Nurix Therapeutics (NASDAQ:NRIX) Posts Quarterly Earnings Results, Misses Estimates By $0.18 EPS

Nurix Therapeutics (NASDAQ:NRIX) posted its quarterly earnings data on Wednesday. The company reported ($0.59) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.41) by ($0.18), Fidelity Earnings reports.

Shares of NRIX traded down $0.75 during midday trading on Thursday, hitting $23.90. The stock had a trading volume of 238 shares, compared to its average volume of 230,128. Nurix Therapeutics has a fifty-two week low of $15.21 and a fifty-two week high of $37.46. The stock’s 50-day moving average price is $27.83.

Several research analysts have commented on the stock. Stifel Nicolaus assumed coverage on shares of Nurix Therapeutics in a report on Tuesday, August 18th. They issued a “buy” rating and a $34.00 target price for the company. JPMorgan Chase & Co. assumed coverage on shares of Nurix Therapeutics in a report on Tuesday, August 18th. They issued an “overweight” rating and a $35.00 target price for the company. Needham & Company LLC assumed coverage on shares of Nurix Therapeutics in a report on Tuesday, August 18th. They issued a “buy” rating and a $35.00 target price for the company. Finally, Piper Sandler assumed coverage on shares of Nurix Therapeutics in a report on Tuesday, August 18th. They issued an “overweight” rating and a $40.00 target price for the company.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company's lead product candidates in preclinical stage include NX-2127, an orally available Bruton's tyrosine kinase degrader for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B inhibitor for immuno-oncology indications.

Featured Article: What is a Futures Contract?

Receive News & Ratings for Nurix Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nurix Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.